Literature DB >> 14711316

Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors.

Qiang Lu1, Ya-Ting Yang, Chang-Shi Chen, Melanie Davis, John C Byrd, Mark R Etherton, Asad Umar, Ching-Shih Chen.   

Abstract

Among various classes of histone deacetylase (HDAC) inhibitors, short-chain fatty acids exhibit the least potency, with IC(50) in the millimolar range. We rationalized that this weak potency was, in part, attributable to their inability to access the zinc cation in the HDAC active-site pocket, which is pivotal to the deacetylation catalysis. We thus explored the structural optimization of valproate, butyrate, phenylacetate, and phenylbutyrate by coupling them with Zn(2+)-chelating motifs (hydroxamic acid and o-phenylenediamine) through aromatic omega-amino acid linkers. This strategy has led to a novel class of Zn(2+)-chelating, motif-tethered, short-chain fatty acids that exhibited varying degrees of HDAC inhibitory potency. One hydroxamate-tethered phenylbutyrate compound, N-hydroxy-4-(4-phenylbutyrylamino)benzamide (HTPB), displayed nanomolar potency in inhibiting HDAC activity. Exposure of several cancer cell lines to HTPB at the submicromolar level showed reduced cell proliferation accompanied by histone hyperacetylation and elevated p21(WAF/CIP1) expression, which are hallmark features associated with intracellular HDAC inhibition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14711316     DOI: 10.1021/jm0303655

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.

Authors:  Hao Cheng; Zhiliang Xie; William P Jones; Xiaohui Tracey Wei; Zhongfa Liu; Dasheng Wang; Samuel K Kulp; Jiang Wang; Christopher C Coss; Ching-Shih Chen; Guido Marcucci; Ramiro Garzon; Joseph M Covey; Mitch A Phelps; Kenneth K Chan
Journal:  AAPS J       Date:  2016-03-04       Impact factor: 4.009

2.  Weak Microbial Metabolites: a Treasure Trove for Using Biomimicry to Discover and Optimize Drugs.

Authors:  Zdenek Dvorak; Max Klapholz; Thomas P Burris; Benjamin P Willing; Antimo Gioiello; Roberto Pellicciari; Francesco Galli; John March; Stephen J O'Keefe; R Balfour Sartor; Chang H Kim; Maayan Levy; Sridhar Mani
Journal:  Mol Pharmacol       Date:  2020-08-06       Impact factor: 4.436

3.  A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Authors:  Douglas W Sborov; Alessandro Canella; Erinn M Hade; Xiaokui Mo; Soun Khountham; Jiang Wang; Wenjun Ni; Ming Poi; Christopher Coss; Zhongfa Liu; Mitch A Phelps; Amir Mortazavi; Leslie Andritsos; Robert A Baiocchi; Beth A Christian; Don M Benson; Joseph Flynn; Pierluigi Porcu; John C Byrd; Flavia Pichiorri; Craig C Hofmeister
Journal:  Leuk Lymphoma       Date:  2017-03-07

4.  Butyrate increases the formation of anti-angiogenic vascular endothelial growth factor variants in human lung microvascular endothelial cells.

Authors:  J Ciura; P P Jagodziński
Journal:  Mol Biol Rep       Date:  2010-03-07       Impact factor: 2.316

5.  Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.

Authors:  Andrew E Shouksmith; Justyna M Gawel; Nabanita Nawar; Diana Sina; Yasir S Raouf; Shazreh Bukhari; Liying He; Alexandra E Johns; Pimyupa Manaswiyoungkul; Olasunkanmi O Olaoye; Aaron D Cabral; Abootaleb Sedighi; Elvin D de Araujo; Patrick T Gunning
Journal:  ACS Med Chem Lett       Date:  2019-12-13       Impact factor: 4.345

6.  Phase I study of AR-42 and decitabine in acute myeloid leukemia.

Authors:  Sophia G Liva; Christopher C Coss; Jiang Wang; William Blum; Rebecca Klisovic; Bhavana Bhatnagar; Katherine Walsh; Susan Geyer; Qiuhong Zhao; Ramiro Garzon; Guido Marcucci; Mitch A Phelps; Alison R Walker
Journal:  Leuk Lymphoma       Date:  2020-02-08

7.  Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors.

Authors:  Sheeba Varghese; Thulani Senanayake; Tracey Murray-Stewart; Kim Doering; Alison Fraser; Robert A Casero; Patrick M Woster
Journal:  J Med Chem       Date:  2008-03-19       Impact factor: 7.446

8.  The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.

Authors:  David M Lucas; Lapo Alinari; Derek A West; Melanie E Davis; Ryan B Edwards; Amy J Johnson; Kristie A Blum; Craig C Hofmeister; Michael A Freitas; Mark R Parthun; Dasheng Wang; Amy Lehman; Xiaoli Zhang; David Jarjoura; Samuel K Kulp; Carlo M Croce; Michael R Grever; Ching-Shih Chen; Robert A Baiocchi; John C Byrd
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

9.  Outer-Sphere Control for Divergent Multicatalysis with Common Catalytic Moieties.

Authors:  Christopher R Shugrue; Bianca R Sculimbrene; Elizabeth R Jarvo; Brandon Q Mercado; Scott J Miller
Journal:  J Org Chem       Date:  2019-01-16       Impact factor: 4.354

10.  Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.

Authors:  Sung Yong Lee; Zhuomin Huang; Tae Heung Kang; Ruey-Shyang Soong; Jayne Knoff; Ellen Axenfeld; Chenguang Wang; Ronald D Alvarez; Ching-Shih Chen; Chien-Fu Hung; T-C Wu
Journal:  J Mol Med (Berl)       Date:  2013-05-29       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.